Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of the Study
2.1.1 Research Objective
2.1.2 Assumptions
2.1.3 Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.1.1 Patent protection expiration of major drugs and growing demand for generic drugs will boost the growth of CMOs globally (Impact weightage 40%)
4.1.2 Competition and economics of production and trade to favour CRO (Impact weightage - 25%)
4.1.3 Mutual benefit to both contract manufacturer and client (Impact weightage - 20% )
4.1.4 Lean manufacturing and agility (Impact weightage - 15%)
4.2 Restraints
4.2.1 Supply Chain Complexity and Issues of Control of 3rd Parties may hamper the market (Impact weightage - 45%)
4.2.2 Standardization and interoperability issues ( Impact weightage - 35% )
4.2.3 Growing cost of noncompliance and counterfeited medicines will reduce the market ( Impact weightage -20% )
4.3 Opportunities
4.4 Challenges
5 Market Factor Analysis
5.1 Porter's Five Force Analysis
5.1.1 Introduction
5.1.2 Threat from a New Entrant
5.1.3 Bargaining Power of Buyer
5.1.4 Bargaining Power of Supplier
5.1.5 Threat from substitute
5.1.6 Intensity of Competitive Rivalry
5.2 Supply Chain Analysis
5.2.1 Raw Material
5.2.2 Supplier
5.2.3 Manufacturer
5.2.4 Distributer
5.2.5 Customer
5.2.6 Consumer
6 Global Pharmaceutical Contract Manufacturing Market By Types
6.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.2 Finished Dosage Formulation (FDF) Market
7 Global Pharmaceutical Contract Manufacturing Market By Regions
7.1 Americas
7.1.1 North America
7.1.1.1 US
7.1.1.2 Canada
7.1.2 SOUTH AMERICA
7.2 Europe
7.2.1 Western Europe
7.2.1.1 Germany
7.2.1.2 France
7.2.1.3 Italy
7.2.1.4 Spain
7.2.1.5 UK
7.2.1.6 REST OF WESTERN EUROPE
7.2.2 Eastern Europe
7.3 Asia Pacific
7.3.1 China
7.3.2 India
7.3.3 Japan
7.3.4 South Korea
7.3.5 Australia
7.3.6 Rest of Asia Pacific
7.4 Middle East & Africa
7.4.1 United Arab Emirates
7.4.2 Saudi Arabia
7.4.3 Oman
7.4.4 Kuwait
7.4.5 Qatar
7.4.6 Rest of Middle East & Africa
8 Company Landscape
9 Company Profile
9.1 Catalant
9.1.1 Company Overview
9.1.2 Financials
9.1.3 Strategy
9.1.4 Key Developments
9.2 Boehringer Ingelheim
9.2.1 Company Overview
9.2.2 Financials
9.2.3 Key Developments
9.3 Lonza AG
9.3.1 Company Overview
9.3.2 Financials
9.3.3 Strategy
9.3.4 Key Developments
9.4 Grifols International, S.A
9.4.1 Company Overview
9.4.2 Financials
9.5 AbbVie Inc
9.5.1 Company Overview
9.5.2 Financials
9.5.3 Key Developments
9.6 Patheon Inc.
9.6.1 Company Overview
9.6.2 Financials
9.6.3 Strategy
9.6.4 Key Developments
9.7 Vetter
9.7.1 Company Overview
9.7.2 Financials
9.7.3 Strategy
9.7.4 Key Developments
9.8 Pharmaceutical Product Development
9.8.1 Company Overview
9.8.2 Financials
9.8.3 Key Developments
10 Conclusion
10.1 Key Findings
10.1.1 From CEO's View Point
10.1.2 Unmet Needs
10.1.3 Prediction of pharmaceutical contract manufacturing Industry
11 Appendix
11.1 Discussion Blue Print